Search
FM-VP4
go.drugbank.com/drugs/DB05449InvestigationalFM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...
Arimoclomol
go.drugbank.com/drugs/DB05025Approved[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337Approved[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.[L53728]
Aliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigational[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.
TBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Propanidid
go.drugbank.com/drugs/DB13234Experimental(From Martindale, The Extra Pharmacopoeia, 30th ed, p918)
OTL-203
go.drugbank.com/drugs/DB18643InvestigationalOTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase geneSinecatechins
go.drugbank.com/drugs/DB01266ApprovedInvestigationalNutraceuticalCatechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin
Synonyms: Polyphenon EProducts: Veregen, VEREGENSulfathiazole
go.drugbank.com/drugs/DB06147ApprovedVet approvedWithdrawnExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.[L43942]